Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease.
Clinical chemistry, 70(10): 1298 PMID 39360998 DOI 10.1093/clinchem/hvae038
Abstract
This article has no abstract in PubMed.
Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.